Aldeyra Therapeutics Price Target Maintained With a $9.00/Share by BTIG
BTIG has maintained its price target for Aldeyra Therapeutics (NASDAQ: ALDX) at $9.00 per share. This indicates the firm's continued outlook on the company's stock performance.
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow (NASDAQ:ALDX) 2026-09-30
Aldeyra Therapeutics, Inc. (ALDX) discussed the FDRR and FDA review process for its drug Reproxalap, which is used for Dry Eye Disease. The company published a slide deck related to this event. This article was written by SA Transcripts, which focuses on publishing quarterly earnings calls and other transcript-related content.
Aldeyra Therapeutics Stock Surges as It Files an FDA Dispute Resolution - Aldeyra Therapeutics (NASDAQ:AL
Aldeyra Therapeutics' stock surged after the company announced its intent to file a formal dispute resolution request with the FDA regarding its reproxalap program for dry eye disease. This move follows an FDA Complete Response Letter that cited a lack of substantial evidence for the drug's efficacy. Investors are reacting positively to the company's decision to fight the rejection, seeing it as a company-specific development rather than a broader sector trend.
Aldeyra to appeal FDA rejection of reproxalap as a treatment for dry eye disease
Aldeyra Therapeutics plans to appeal the FDA's rejection of its investigational drug, reproxalap, for dry eye disease by submitting a Formal Dispute Resolution Request (FDRR). The company will appeal the March 16, 2026 Complete Response Letter which stated that the totality of evidence from completed clinical trials did not support the product's effectiveness, despite Aldeyra's claim of nine adequate trials. Aldeyra expects to submit the FDRR and meet with the FDA's Office of New Drugs in the fourth quarter of 2026.
Aldeyra to Appeal FDA Rejection of Reproxalap for Dry Eye Disease
Aldeyra Therapeutics plans to appeal the FDA's rejection of reproxalap for dry eye disease through a formal dispute resolution request. The company argues that the totality of nine clinical trials supports the treatment's effectiveness, despite the FDA's conclusion that the overall evidence was insufficient. Aldeyra expects to meet with the FDA in Q4 2026 and has updated its cash runway guidance to fund operations into 2029, while suspending development of ADX-2191 to conserve resources.
Aldeyra to appeal FDA rejection of dry eye drug reproxalap
Aldeyra Therapeutics plans to appeal the FDA's rejection of its dry eye drug, reproxalap, by submitting a Formal Dispute Resolution Request in Q4 2026. The company seeks to overturn a Complete Response Letter that denied approval, despite having provided data from nine clinical trials. Aldeyra has also updated its financial guidance, extending its operational cash runway into 2029.
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com
This article announces that Aldeyra Therapeutics Inc. filed a Form 8K on September 29. The filing is a standard corporate disclosure that companies submit to the SEC to announce significant events that shareholders should know about.
After three FDA denial letters, Aldeyra plans a formal challenge over its dry eye drug.
Aldeyra Therapeutics announced its intent to submit a Formal Dispute Resolution Request (FDRR) to the FDA regarding its dry eye drug, reproxalap, following three Complete Response Letters denying approval. The company plans to appeal the most recent denial, which cited a lack of sufficient evidence for effectiveness despite nine clinical trials. Aldeyra expects the FDRR submission and a meeting with the FDA's Office of New Drugs in Q4 2026 and has extended its operational cash runway into 2029.
Form 8K Aldeyra Therapeutics Inc For: 29 September By Investing.com
This article announces that Aldeyra Therapeutics Inc. filed a Form 8K on September 29, 2026. The filing is a standard regulatory disclosure for material events that shareholders should know about. The content provides the title of the filing and indicates its publication by Investing.com.
Aldeyra Therapeutics Plans Formal FDA Dispute Resolution Request for Reproxalap After Third Complete Response Letter
Aldeyra Therapeutics announced its intention to file a Formal Dispute Resolution Request with the FDA to appeal the rejection of reproxalap for dry eye disease. This decision follows the third Complete Response Letter from the FDA, which stated the existing clinical trial evidence did not support the drug's effectiveness, though it did not request another trial. Aldeyra expects to submit the request and meet with the FDA's Office of New Drugs in Q4 2026, and has extended its operational cash runway into 2029.
Aldeyra Therapeutics Announces Intent to Submit Formal Dispute Resolution Request for Reproxalap to Treat Dry Eye Disease
Aldeyra Therapeutics plans to submit a Formal Dispute Resolution Request (FDRR) to the FDA regarding its investigational drug reproxalap for dry eye disease, following three Complete Response Letters denying approval. The company aims to appeal the FDA's decision, citing data from nine clinical trials, and anticipates a meeting with the FDA's Office of New Drugs in Q4 2026. Aldeyra also updated its financial guidance, extending its operational cash runway into 2029.
Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics announced it will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The webcast will focus on reproxalap, an investigational drug for the treatment of dry eye disease. A live audio webcast and slide presentation will be available on the company's "Investors & Media" section for 90 days following the event.
Aldeyra Therapeutics to Host Regulatory Update Webcast
Aldeyra Therapeutics will host a regulatory update webcast on Tuesday, September 29, 2026, at 8:00 a.m. ET. The webcast will focus on reproxalap, an investigational drug for dry eye disease. A live audio webcast and slide presentation will be available on the company's website.
Aldeyra Therapeutics, Inc. (ALDX) Options Chain
This page provides the options chain for Aldeyra Therapeutics, Inc. (ALDX), detailing call and put options. As of the data presented, there were no available calls or puts for ALDX. The stock was trading at $1.4650, down 1.01%.
Aldeyra Therapeutics (NASDAQ:ALDX) Lowered to "Sell" Rating by Wall Street Zen
Aldeyra Therapeutics (NASDAQ:ALDX) has been downgraded from a "Hold" to a "Sell" rating by Wall Street Zen, and Weiss Ratings also lowered its assessment. Despite the downgrades, the company met quarterly earnings expectations with a loss of $0.09 per share, and its CEO recently purchased 250,000 shares. Institutional investors and hedge funds hold a significant portion of the company's stock, while analysts maintain a consensus "Hold" rating with an average price target of $5.50.
Aldeyra Therapeutics (ALDX): AQR Capital discloses 6.22% beneficial ownership stake
AQR Capital Management, LLC and its parent company, AQR Capital Management Holdings, LLC, have disclosed a beneficial ownership stake of 6.22% in Aldeyra Therapeutics, Inc. (ALDX), totaling 3,751,558 shares of common stock. Both entities report shared voting power over 3,381,606 shares and shared dispositive power over all 3,751,558 shares. This disclosure, filed under SCHEDULE 13G, indicates a passive investment.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) on behalf of investors who purchased securities between November 3, 2023, and March 16, 2026. The lawsuit alleges that Aldeyra made false and misleading statements regarding inconsistent results from its reproxalap clinical trials. Investors who suffered losses have until May 29, 2026, to apply to be lead plaintiff.
ALDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX). The lawsuit alleges that Aldeyra made false and misleading statements regarding the inconsistent results of clinical trials for their drug candidate, reproxalap. Investors who suffered losses between November 3, 2023, and March 16, 2026, are encouraged to join the lawsuit, with a lead plaintiff deadline of May 29, 2026.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX) who bought securities prior to November 3, 2023. The investigation focuses on whether Aldeyra's officers and/or directors engaged in corporate wrongdoing. The firm encourages affected shareholders to connect through their website for more information and assistance with the investigation, with no upfront cost to investors.
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
Aldeyra Therapeutics Inc (ALDX) has an earnings forecast score of 8.67, ranking 75th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.50, with a strong "Buy" rating based on the consensus of 6 analysts. The company's expected revenue for the next quarter is $24.25 million, and EPS for the next quarter is projected at -$0.10.
Aldeyra Therapeutics (NASDAQ:ALDX) Announces Quarterly Earnings Results
Aldeyra Therapeutics (NASDAQ:ALDX) reported a quarterly loss of $0.09 per share, missing analyst estimates by $0.01. Shares dropped 0.6% to $1.59, trading below their moving averages, and the company has a market capitalization of $95.9 million. Despite the earnings miss, CEO Todd C. Brady increased his stake by purchasing 250,000 shares, and analysts maintain a consensus "Hold" rating with a target price of $5.50.
Aldeyra Therapeutics, Inc. Q2 2026: Net loss $5.45M, EPS $(0.09) — 10-Q Summary
Aldeyra Therapeutics, Inc. reported a significant reduction in its net loss for Q2 2026, reaching $5.45M compared to $9.77M in Q2 2025, with diluted EPS improving to $(0.09). This improvement is attributed to reduced R&D activity and controlled spending, as the company continues to advance its development programs for reproxalap and ADX-2191. The company maintains an exclusive option with AbbVie for reproxalap commercialization and has sufficient cash to fund operations into the second half of 2028.
ALDX STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Aldeyra Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Bronstein, Gewirtz and Grossman, LLC has announced a class action lawsuit against Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) and its officers. The lawsuit alleges that the company made false and misleading statements regarding the inconsistent results of its reproxalap clinical trials. Investors who purchased Aldeyra securities between November 3, 2023, and March 16, 2026, and suffered losses, have until May 29, 2026, to seek lead plaintiff status.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) regarding potential corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to join the investigation. Bronstein, Gewirtz & Grossman, LLC operates on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Aldeyra Therapeutics, Inc. (ALDX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) on behalf of investors who purchased securities before November 3, 2023, and still hold them. The investigation focuses on whether Aldeyra's officers or directors engaged in corporate wrongdoing. The firm encourages affected shareholders to contact them to learn more about the investigation, noting they operate on a contingency fee basis.
Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) Short Interest Update
Aldeyra Therapeutics (NASDAQ:ALDX) experienced a 36.7% decrease in short interest by July 15th, totaling 3.59 million shares, representing 6.8% of outstanding shares and a two-day days-to-cover ratio. CEO Todd C. Brady recently increased his stake by nearly 17% through a purchase of 250,000 shares valued at $417,500. Analysts maintain a consensus "Hold" rating with a $5.50 price target, despite the stock trading significantly below its 12-month high.
Aldeyra Therapeutics (NASDAQ: ALDX) leases new Concord headquarters space
Aldeyra Therapeutics (NASDAQ: ALDX) has signed a lease for a new corporate headquarters located at 23 Bradford Street, Concord, Massachusetts, encompassing approximately 4,067 square feet. The lease, which commences on September 1, 2026, and runs through September 30, 2029, involves an initial monthly base rent of $12,201.00, escalating annually, in addition to operating expenses and taxes. The company will also provide a $50,000.00 security deposit for the new space.
Aldeyra Therapeutics Inc (ALDX) Valuation: PE, PB & Fair Value Analysis
Aldeyra Therapeutics Inc (ALDX) currently holds a valuation score of 8.18, placing it 160th out of 384 companies in the Biotechnology & Medical Research industry. The company's P/E ratio is -3.54, which is significantly below its recent high and above its recent low. Important P/B and P/CF data have not yet been disclosed by the company.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX). The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to come forward and assist in the investigation. They operate on a contingency fee basis, aiming to recover investor capital and ensure corporate accountability.
Aldeyra Therapeutics Inc (ALDX) Institutional Confidence
Aldeyra Therapeutics Inc (ALDX) has an institutional shareholding score of 5.00, ranking 132nd in the Biotechnology & Medical Research industry. Institutional shareholding increased by 5.38% quarter-over-quarter, reaching 65.57%. Knoll Capital Management, LLC is the largest reported institutional shareholder, holding 5.48M shares.
Aldeyra Therapeutics Inc (ALDX) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Aldeyra Therapeutics Inc (ALDX), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The stock (ALDX) is currently trading within a range, with indicators showing a mix of buy, sell, and neutral signals, leading to an overall neutral signal based on moving averages and technical indicators.
BlackRock (ALDX holder) discloses 1.7% Aldeyra Therapeutics stake in amended 13G
BlackRock, Inc. has filed an amended Schedule 13G, revealing a beneficial ownership of 1,045,764 common shares in Aldeyra Therapeutics, Inc. (ALDX), which constitutes a 1.7% stake in the company. BlackRock maintains sole voting and dispositive power over all these shares. This filing specifies that while various entities within BlackRock hold these securities, no single person's interest surpasses five percent of Aldeyra's outstanding common stock.
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) on behalf of investors who purchased securities prior to November 3, 2023. The investigation aims to determine if the company and its officers engaged in corporate wrongdoing. The firm encourages affected stockholders to contact them for more information regarding the securities investigation.
Aldeyra Therapeutics Inc (ALDX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for Aldeyra Therapeutics Inc (ALDX). However, it states that relevant data for business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page displays basic stock information and a placeholder indicating the absence of this specific financial data.
Aldeyra Therapeutics Inc (ALDX) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Aldeyra Therapeutics Inc (ALDX), detailing its volatility, financial risks, and investment risks. It presents various financial metrics such as Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, Skewness, Downside Risk-Adjusted Return, and Liquidity. The data covers different timeframes, offering a comprehensive overview of the stock's risk profile.
Aldeyra Therapeutics, Inc. Revenue Breakdown – NASDAQ:ALDX
This article provides financial overview and revenue breakdown information for Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) on the TradingView platform. It highlights fundamental and statistical data, including statements, dividends, earnings, and segments, with a focus on revenue sources and regional performance.
Aldeyra Therapeutics Inc (ALDX) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Aldeyra Therapeutics Inc (ALDX), noting its current earnings forecast score of 8.67 within the Biotechnology & Medical Research industry. Analysts have set an average price target of $9.50, with a consensus "Buy" rating based on the assessment of six analysts. The report also details past and expected future EPS figures for the company.
Aldeyra Therapeutics Inc (ALDX) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Aldeyra Therapeutics Inc (ALDX), outlining its major shareholders, institutional holdings, and shareholder activity. It identifies top shareholders like Knoll Capital Management and Perceptive Advisors, categorizes shareholder types, and presents quarterly institutional shareholding data and recent changes in major holdings.
ALDX|Aldeyra Therapeutics Inc|Price:1.520|Chg%:-0.030
This article provides a comprehensive stock analysis of Aldeyra Therapeutics Inc (ALDX) using TradingKey's proprietary scoring system. It highlights the company's strong fundamentals and high growth potential, fair valuation within its industry, and high institutional ownership. Despite recent stock market weakness, analysts have rated ALDX as a 'Buy' with a target price suggesting significant upside.
ALDX Q2'26 Earnings: revenue estimate is 0 USD
Aldeyra Therapeutics, Inc. (ALDX) is scheduled to announce its Q2'26 earnings on July 31st. The company is projected to report 0 USD in revenue and an EPS of (0.08) USD for the quarter. This article provides a brief overview of past and estimated revenue and EPS figures for ALDX.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Aldeyra Therapeutics, Inc. (ALDX) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Aldeyra Therapeutics, Inc. (ALDX) regarding potential corporate wrongdoing by the company and its officers/directors. Investors who purchased Aldeyra securities before November 3, 2023, and still hold them, are urged to contact the firm to assist with the investigation. The firm operates on a contingency fee basis, only seeking reimbursement if successful in recovering funds for investors.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Investors to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and its officers/directors. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis, aiming to recover investor capital through class actions and shareholder derivative suits.
Price to sales forward of Aldeyra Therapeutics, Inc. – FWB:137
This article displays the "Price to sales forward" metric for Aldeyra Therapeutics, Inc. (FWB:137) as presented on TradingView. The content is a data point from a financial platform, showing a specific financial ratio for the company, and highlights that the market was closed with no trades.
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Aldeyra Therapeutics, Inc. (ALDX) And Encourages Stockholders to Reach Out
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into potential corporate wrongdoing by Aldeyra Therapeutics, Inc. (ALDX) and certain officers/directors. The firm is encouraging stockholders who purchased Aldeyra securities before November 3, 2023, and still hold them, to contact them to assist with the investigation. The firm operates on a contingency fee basis for these types of investor class actions.
Aldeyra Therapeutics to seek Type D meeting with FDA on reproxalap NDA resubmission
Aldeyra Therapeutics plans to request a Type D meeting with the FDA to discuss a potential New Drug Application (NDA) resubmission for reproxalap, a treatment for dry eye disease. This decision follows their request for clarification on FDA minutes from a June 10, 2026 Type A meeting. The Type D meeting is anticipated by the end of Q3 2026 to progress resubmission discussions.
Aldeyra Therapeutics (NASDAQ: ALDX) advances FDA dialogue on reproxalap NDA
Aldeyra Therapeutics (NASDAQ: ALDX) reported ongoing regulatory discussions with the FDA concerning the New Drug Application (NDA) for reproxalap, intended for dry eye disease treatment. The company received minutes from a Type A meeting on July 14, 2026, and is now seeking clarification while planning a Type D meeting with the FDA by the end of Q3 2026 to further address the potential NDA resubmission. This report highlights Aldeyra's proactive engagement with the FDA following a previous Complete Response Letter related to the drug.
Aldeyra Therapeutics (ALDX) Short Interest & Short Float | Updated Jul 2026
Aldeyra Therapeutics (ALDX) saw a significant decline in short interest during June 2026, with the total number of shares sold short decreasing by 17.34% to 5.68 million shares. This represents 10.67% of the public float and a short interest ratio of 2.5 days to cover. The change indicates a shift towards more bullish sentiment among investors for ALDX stock.
Aldeyra Therapeutics Inc. (ALDX) Stock Price | Live Quotes & Charts | NASDAQ
This page provides live quotes and charts for Aldeyra Therapeutics Inc. (ALDX) stock. It includes current stock price, financial details, and analyst ratings, noting that there are no current analyst ratings or earnings information available for ALDX. The page also features a disclaimer about the risks and typical losses associated with day trading.
Bronstein, Gewirtz & Grossman, LLC Encourages Aldeyra Therapeutics, Inc. (ALDX) Shareholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Aldeyra Therapeutics, Inc. (ALDX) securities. The investigation focuses on whether Aldeyra and its officers engaged in corporate wrongdoing, particularly for investors who bought shares before November 3, 2023. The law firm encourages affected shareholders to contact them to assist with the investigation, noting that they operate on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Aldeyra Therapeutics, Inc. (ALDX) And Encourages Shareholders to Connect
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims against Aldeyra Therapeutics, Inc. (ALDX) for alleged corporate wrongdoing. The firm is encouraging investors who purchased Aldeyra securities before November 3, 2023, and still hold them, to connect and assist with the investigation. The representation of investors in class actions is on a contingency fee basis.
